Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice

Figure 3

Chronic elafibranor treatments improved the renal function through the activation of renal SIRT1 in HFD mice with steatohepatitis and CKD. (a) Mean arterial blood pressure (MAP, mmHg); (b) serum creatinine (mg/dL); (c) PPAR α/δ; and (d-e) energy nutrient sensor markers mRNA levels (%/18S) in main target tissue of HFD mice; (f) liver and renal SIRT1 activity (RFU, relative fluorescence units). p<0.05,0.01 versus NC-group; p<0.05, 0.01 versus HFD-group; p<0.05 versus HFD-elaf group.

(a)

(b)

(c)

(d)

(e)

(f)